Senior Director, Pharmacometrics
Immunome, Inc.
| Company | Immunome, Inc. |
| Category | Healthcare |
| Location | Bothell |
| Remote | On-site (inferred) |
| Employment | Not stated |
| Level | Director |
| Salary | Not stated by the employer |
| Posted | 25 Jun 2026 |
| Last verified | 9 Aug 2026 |
| Source | Employer ATS (greenhouse) |
Description
Company Overview
Immunome is a clinical-stage targeted oncology company committed to developing first-in-class and best-in-class targeted cancer therapies. We are advancing an innovative portfolio of therapeutics, supported by a leadership team with deep experience in the design, development, and commercialization of cutting-edge therapies, including antibody-drug conjugates. Our pipeline includes varegacestat, an investigational gamma secretase inhibitor for which an NDA has been submitted to the U.S. FDA; IM-1021, a clinical-stage ROR1 ADC; IM-3050, an IND-cleared FAP-targeted radiotherapy; and IM-1617, an IND-cleared solid tumor ADC. We are also advancing a broad portfolio of early-stage ADCs pursuing undisclosed solid tumor targets. Position Overview
Immunome is seeking a highly experienced and strategic Senior Director, Pharmacometrics to lead model-informed drug development strategies across Immunome’s targeted oncology portfolio. This role will be responsible for the design, execution, interpretation, and communication of pharmacometric analyses that support clinical development decisions, dose selection and optimization, regulatory submissions, and product labeling.
The successful candidate will bring deep technical expertise in population PK, PK/PD, exposure-response, simulation, and fit-for-purpose application of PBPK, QSP, or other quantitative modeling approaches. This position offers a highly visible leadership opportunity to shape Immunome’s pharmacometrics strategy, influence program and portfolio decisions, and advance innovative oncology therapeutics from early clinical development through registration and lifecycle management.
Responsibilities
Strategic Leadership
Develop and implement pharmacometrics strategies across clinical development programs, ensuring quantitative approaches are aligned with program objectives , clinical pharmacology plans, and regulatory expectations.
Serve as the pharmacometrics strategy lead for assigned programs, providing scientific leadership for dose selection, dose optimization, exposure-response assessment, and model-informed decision-making.
Contribute to the long-term vision for Immunome’s quantitative clinical pharmacology capabilities, including standards for modeling, simulation, documentation, and cross-functional integration.
Modeling, Simulation, and Quantitative Strategy
Lead the development and execution of population PK, PK/PD, exposure-response, disease progression, and model-based meta-analysis strategies to support clinical development and registration.
Apply fit-for-purpose PBPK, QSP, translational modeling, or simulation approaches to inform first-in-human strategy, dose escalation, dose expansion, special populations, drug-drug interaction risk, and lifecycle development.
O versee analysis plans, model development, simulations, quality control, and interpretation of pharmacometric outputs to ensure scientific rigor, reproducibility, and regulatory readiness .
Program Oversight and Execution
Partner with Clinical Pharmacology, Clinical Development, Biostatistics, ADME , Translational Science, Bioanalytical, Regulatory, Clinical Operations, Data Management, and Medical Writing to integrate pharmacometrics deliverables into development plans and study timelines.
Provide input into clinical protocols, sparse and intensive PK/PD sampling strategies, statistical analysis plans, data standards, and integrated evidence generation plans.
Serve as the primary pharmacometrics representative on cross-functional program teams and governance forums, translating quantitative findings into clear development r